The Selection Committee bestowed prizes in the categories of Russian R&D and Innovation to Generium and the Engelhardt Institute, and to Pfizer, AstraZeneca and Roche Diagnostics in the categories of International Innovation.
Yesterday evening the Prix Galien Russia Awards Committee honored excellence in research, development and innovation in the biomedical industry at its second award ceremony held at the Pashkov House.
This year the Committee awarded laureates in a total of five categories: Russian Biopharmaceutical R&D, Russian Medical Technology R&D, Best Biotechnology Product, Best Pharmaceutical Agent and Best Medical Technology.
In the category of Russian Biopharmaceutical R&D the Galien award went to Generium in cooperation with the Moscow State Research and Practice Center for Tuberculosis Control (Moscow Department of Health) for their biotechnology product Diaskintest® that serves to identify tuberculosis infections in adults and children.
The 2014 Prix Galien Russia Award for Russian Medical Technology R&D was presented to the Engelhardt Institute of Molecular Biology of Russian Academy of Science for their work on hydrogel biochips technology for medical diagnostics.
For the first international category of Best Biotechnology Product, the 2014 award went to Pfizer’s Prevenar 13® (Pneumococcal 13-valent Conjugate Vaccine – Diphtheria CRM 197 Protein).
In the category of Best Pharmaceutical Agent the jury selected AstraZeneca for their product Brilinta® (Ticagrelor), which, when co-administered with acetylsalicylic acid, is indicated for the prevention of atherothrombotic events in adult patients with аcute сoronary syndromes, including patients managed medically, and those who are managed with percutaneous coronary intervention or coronary artery by-pass grafting.
In the final category of Best Medical Technology the 2014 Prix Galien Russia award went to Roche Diagnostics for their Cobas® 4800 HPV test.
Additional to the Galien laureates, this year’s ceremony also included the Pro Bono Huminum award that was granted to the Deti Bela Foundation and Ksenia Rappoport for their commendable action to offer hope and practical care to children affected with Epidermolysis Bullosa (EB).
About the Prix Galien Russia
The Prix Galien Russia was inaugurated in Moscow, Russia on the 24 of October 2013 under the auspice of an exceptional awards committee composed of eminent specialists involved in the sphere of Russian and international pharmaceutical research. The award is supported by the Russian Ministry of Health.
Around the world, the Prix Galien awards outstanding achievements in improving the human condition through the development of innovative therapies and technologies.
For additional information please visit www.prixgalienrussia.com or us at prixgalien@focusreports.net
